Barrons : Stocks To Watch (58)

Calgon Carbon: Kuraray Pays Up….Big

Calgon Carbon's share price continues to surge on news of its $1.1 billion merger with a Japan's Kuraray. Yet some analysts warn that Kuraray is overpaying for the deal.

Biogen: Buy or Hold?

One analyst launched coverage on the biotech giant at a Buy, while another downgraded the stock to Market Perform. The two analysts have very different outlooks for Biogen's multiple sclerosis franchise.

Hanesbrands: Time to Lock In Profits?

An Instinet analyst downgraded the apparel maker to Neutral amid worries that retail faces a difficult holiday season.

Morning Movers: Calgon Carbon Surges, Biogen Slips, AMD Gains

All the market-moving news you need to know this morning including reports of a possible deal between AMD and Tesla, a downgrade for Biogen and an earnings beat for Scholastic.

The Hot Stock: Advanced Micro Devices Jumps 4.7%. Thanks Tesla!

Teaming with Tesla made Advance Micro Devices the best-performing stock in the S&P 500 today.

The Biggest Loser: General Mills Tumbles 5.7%

A big earnings miss made General Mills the worst-performing stock in the S&P 500 today.

The Hottest Stock: Chesapeake Energy Gains 3.7%

Higher oil prices made Chesapeake Energy the second-best performing stock in the S&P 500 today.

3 Reasons Intercept Pharma Could Surge 180%

Bernstein's Michael Yee says this battered drug maker could skyrocket to $275 a share. Here's why.

Apache: Can An Alpine High Lift This Depressed Stock?

Bernstein analysts say now is a good time to enter the fray.' Here's why.

J&J: You Can Only Stretch That Valuation So Far

Goldman Sachs analyst Jami Rubin says it is time to sell J&J. Here's why.

Uh Oh. JPMorgan's Tusa Just Cut 3M to Underweight

JPMorgan's long-time General Electric bear, just made 3M his second Underweight-rated stock.

L Brands: Sorry, You're Just Too Challenging to Stick With

One long-time bull cut his rating on L Brands despite still seeing many positives.

Pfizer: Is It Time To Buy?

Morgan Stanley's David Risinger says it's time to buy the pharmaceutical giant. Pfizer. Here's why.

General Mills: Cereal-sly Bad

Shares of General Mills are tumbling today after reporting weaker-than-expected earnings.

Allergan: Just How Far Will Big Pharma Go To Protect Its Patents?

Allergan's deal with the Saint Regis Mohawk Tribe may allow it to sidestep a patent review by the U.S. Patent & Trademark Office, but it has raised some questions. One major industry analysts cited the deal as one of three reasons for its recent downgrade of Allergan's stock.

Bed Bath & Beyond: I've Got Some Bad News…and Some Worse News

Shares of Bed Bath & Beyond are tumbling after releasing earnings and guidance that one analyst calls "disastrous."

American Airlines: Is It a $75 Stock?

An analyst at Raymond James upgraded the airline to Outperform and set a $58 price target. Yet she also offered up a bullish argument for why the stock could climb even higher.

Fed Up! Even the End of QE Can't Keep the Dow From Hitting an All-Time High

The Dow hit a new high today following the Fed's decision today to shrink its balance sheet.

FedEx: You're Forgiven

The cyberattack on FedEx's TNT Express in June dented per share earnings for the quarter. But these analysts remain bullish on the stock.

Wal-Mart: Why the Toys 'R' Us Bankruptcy Is Good News

One team of analysts concludes that a Toys 'R' Us bankruptcy could allow Wal-Mart and Amazon.com to gain market share in the toy business.

Morning Movers: General Mills Slumps, Johnson & Johnson Slips, American Airlines Gains

All the market-moving news you need to know this morning including earnings from General Mills, Bed Bath & Beyond and FedEx, downgrades for 3M, L Brands and Johnson & Johnson, and an Upgrade for American Airlines.

Three's a Crowd! Dow Gains 40 Points, Hits New High as Fed on Deck

All three major indexes closed at new highs today as tomorrow's Fed meeting inspired little fear.

FedEx: Now That Wasn't So Bad…

FedEx's stock is dropping after releasing earnings--but not as much as some had feared.

The Hot Stock: Leucadia National Climbs 3.9%

Leucadia National was the best performing stock in the S&P 500 today thanks to strong results from Jefferies' investment-banking unit.

The Biggest Loser: Envision Healthcare Slumps 9.6%

Envision Healthcare was the worst-performing stock in the S&P 500 today.

Healthcare Reform: Who Suffers?

As the latest effort to repeal the landmark Affordable care Act gains momentum in the Senate, Leerink analysts look at which health care companies could suffer most. 

Michael Kors: Too Cheap?

Analysts at Oppenheimer see Michael Kors climbing 20% over the next year. He's why they say its time to buy the handbag giant.

Under Armour: Time To Sell?

Wells Fargo analysts downgraded the stock to an Underperform and cut their price target to $13 a share. Here's why.

Disney: Like, So Misunderstood

One analyst claims that Disney's streaming service could mean big upside--and compare it favorably to World Wrestling Entertainment.

Teva: Now What?

Teva Pharmaceutical Industries is getting a bit of credit today. The shares inched higher after the troubled drug maker announced changes to debt covenants, which the company says will provide better flexibility. Bloomberg News MarketWatch writer Emma Court offered up these details regarding how ...

Chesapeake Energy: Great Assets, Too Bad About the Debt

One team of analysts explains why it's cautious on Chesapeake Energy.

Best Buy: 2021 Guidance Is No Gift; Shares Drop

The nation's largest electronics retailer plunged after the new 2021 financial targets it unveiled today failed to impress the Street.

AutoZone: Amazon Trumps Good Earnings

The auto parts retailer's share price is falling sharply despite its fiscal fourth quarter earnings beat.

Why Credit Suisse Warmed Up To Gap

Analysts at Credit Suisse upgraded the struggling clothing retailer to a Neutral. Here's why. 

Nike: Another Bull Bites The Dust

Is Nike on track to hit $50 billion in sales by 2020. Susquehanna's Sam Poser warns that target looks elusive.'

Tesla: Fail to Deliver?

A day after Tesla closed at an all-time high, one team of analyst starts Tesla with an Underperform rating and a $280 price target.

Morning Movers: Under Armour & Nike Slump, while Gap & Kors Gain

All the market-moving news you need to know this morning including upgrades for Gap, Kors, McKesson, and Melco, downgrades for Under Armour and Nike, earnings from AutoZone, and a Tesla initiation.

I Can See Clearly Now: Dow Gains 63 Points, Hits New High as Old Bull Lives On

The Dow and the S&P 500 hit new highs today. And why not?

The Hot Stock: CF Industries Jumps 6.7%

CF Industries was the best-performing stock in the S&P 500 today.

The Biggest Loser: Mattel Tumbles 6.2%

Mattel tumbled to the bottom of the S&P 500 today on reports that Toys R Us is considering filing for bankruptcy. Getty Images Mattel dropped 6.2% to $14.87 today, while the S&P 500 rose 0.2% to 2503.87. Hasbro fell 1.7% to $93.23. The Wall Street Journal's Lillian Rizzo and Soma Biswas ...

United Continental: Now That's a Cut!

Another day, another downgrade for United Continental, as analysts continue to question its priorities.

BP: Boring is Beautiful

One team of analysts argues that BP's refining business brings in enough cash flow to cover 60% of the dividend, and upgrades the stock accordingly.

Teva: When Bold Action Just Isn't Possible

One team of analysts writes that there are no easy ways to fix Teva.

Caterpillar: Autonomous Driving Isn't Just For Cars

An analyst argues that a push into autonomous machinery is one reason to be bullish on Caterpillar.

Why Allergan Could Be A $300 Stock

J.P. Morgan's Chris Schott says Wall Street is overlooking the drug maker's highly attractive' core franchises. Here's why he sees the stock climbing as much as 33% over the next year.

Northrop Grumman: Buying It's Way Into the Final Frontier?

Shares of Northrop Grumman are gaining today after it announced the acquisition of satellite maker Orbital ATK.

Gilead Sciences: Is The Kite Deal Too Little, Too Late?

Leerink's Geoffrey Porges and Bradley Canino raised their price target on the drug maker's stock to $87 a share, but maintained a Market Perform rating. Here's why.

Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon?

The drug maker could receive a long-awaited approval for a new glaucoma drug and clear up regulatory concerns surrounding its Tampa manufacturing plant.

Nike: Time to Panic?

One team of analysts contends that investors could be starting to losing patience with Nike.

Tesla: Spitting Into a Hurricane?

Shares of Tesla could close at a new all-time high today. One analyst sees plenty of reasons for the stock to keep rallying.